MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamaoncol.2018.0211

Медицинская библиотека · JAMA oncology · 2018

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

Kotsopoulos Joanne, Gronwald Jacek, Karlan Beth Y, Huzarski Tomasz, Tung Nadine, Moller Pal, Armel Susan, Lynch Henry T, Senter Leigha, Eisen Andrea, Singer Christian F, Foulkes William D, Jacobson Michelle R, Sun Ping, Lubinski Jan, Narod Steven A, Hereditary Breast Cancer Clinical Study Group

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

IMPORTANCE

Prophylactic bilateral salpingo-oophorectomy is recommended for BRCA1 mutation carriers to prevent ovarian cancer. Whether or not hormone replacement therapy (HRT) initiated after oophorectomy is associated with an increased risk of breast cancer has not been evaluated in a prospective study.

OBJECTIVE

To determine the association between HRT use and BRCA1-associated breast cancer.

DESIGN, SETTING, AND

PARTICIPANTS

A prospective, longitudinal cohort study of BRCA1 and BRCA2 mutation carriers from 80 participating centers in 17 countries was conducted between 1995 and 2017 with a mean follow-up of 7.6 years. Participants had sought genetic testing for a BRCA1 or BRCA2 mutation because of a personal or family history of breast and/or ovarian cancer. Carriers of BRCA1 mutation with no personal medical history of cancer who underwent bilateral oophorectomy following enrollment were eligible for the cohort study.

EXPOSURES: A follow-up questionnaire was administered every 2 years to obtain detailed information on HRT use. A left-truncated Cox proportional hazard analysis was used to estimate the hazard ratios (HRs) and 95% CIs associated with the initiation of HRT use postoophorectomy.

MAIN OUTCOMES AND MEASURES: Incident breast cancer.

RESULTS

A total of 872 BRCA1 mutation carriers with a mean postoophorectomy follow-up period of 7.6 years (range, 0.4-22.1) were included in this study. Mean (SD) age of participants was 43.4 (8.5) years. Among these, 92 (10.6%) incident breast cancers were diagnosed. Overall, HRT use after oophorectomy was not associated with an increased risk of breast cancer. The HR was 0.97 (95% CI, 0.62-1.52; P = .89) for ever use of any type of HRT vs no use; however, the effects of estrogen alone and combination hormonal therapy were different. After 10 years of follow-up, the cumulative incidence of breast cancer among women who used estrogen-alone HRT was 12% compared with 22% among women who used estrogen plus progesterone HRT (absolute difference, 10%; log rank P = .04).

CONCLUSIONS AND RELEVANCE: These findings suggest that use of estrogen after oophorectomy does not increase the risk of breast cancer among women with a BRCA1 mutation and should reassure BRCA1 mutation carriers considering preventive surgery that HRT is safe. The possible adverse effect of progesterone-containing HRT warrants further study.

Для цитирования: Kotsopoulos Joanne, Gronwald Jacek, Karlan Beth Y, Huzarski Tomasz, Tung Nadine, Moller Pal, Armel Susan, Lynch Henry T, Senter Leigha, Eisen Andrea, Singer Christian F, Foulkes William D, Jacobson Michelle R, Sun Ping, Lubinski Jan, Narod Steven A, Hereditary Breast Cancer Clinical Study Group. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.. JAMA oncology. 2018. DOI: 10.1001/jamaoncol.2018.0211.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.